Ignite Creation Date:
2025-12-26 @ 10:58 AM
Ignite Modification Date:
2025-12-29 @ 3:16 PM
Study NCT ID:
NCT05588908
Status:
UNKNOWN
Last Update Posted:
2022-10-20
First Post:
2022-10-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06-29
Start Date Type:
ACTUAL
Primary Completion Date:
2023-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-11
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-17
First Submit QC Date:
None
Study First Post Date:
2022-10-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-17
Last Update Post Date:
2022-10-20
Last Update Post Date Type:
ACTUAL